Parkinson’s disease (PD) shares pathological and clinical features with progressive supranuclear palsy (PSP) patients making the diagnosis challenging. Distinguishing PD from PSP is crucial given differences in disease course, treatment and clinical management.
Objective:
Although some progress has been made in the discovery of biomarkers for PD and PSP, there is an urgent need to identify additional biomarkers capable of distinguishing between these diseases.
Methods:
In this study, we tested the phosphatases DUSP8 and PTPRC for their diagnostic potential using quantitative PCR assays, in blood of 138 samples from participants nested in the Parkinson’s Disease Biomarkers Program.
Results:
Relative abundance of PTPRC mRNA was downregulated in PSP patients compared to PD and healthy controls, whereas there was no significant difference in the expression of DUSP8. Interestingly, PTPRC mRNA correlated with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total score and MDS-UPDRS- part III, thus indicating it might be useful as part of a biosignature to stratify patients according to disease severity and progression.
Conclusions:
Collectively, these results suggest that PTPRC expression may be useful for distinguishing PD from PSP patients as part of a biosignature. Evaluation of PTPRC along with additional biomarkers in a larger and well-characterized longitudinal study is warranted.
PringsheimT, JetteN, FrolkisA, SteevesTD (2014) The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov Disord29, 1583–1590.
2.
SchapiraAH, OlanowCW, GreenamyreJT, BezardE (2014) Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: Future therapeutic perspectives. Lancet384, 545–555.
3.
PoeweW, WenningG (2002) The differential diagnosis of Parkinson’s disease. Eur J Neurol9(Suppl 3), 23–30.
4.
RajputAH, RajputA (2014) Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology83, 386–387.
5.
LiscicRM, SrulijesK, GrogerA, MaetzlerW, BergD (2013) Differentiation of progressive supranuclear palsy: Clinical, imaging and laboratory tools. Acta Neurol Scand127, 362–370.
6.
TangCC, PostonKL, EckertT, FeiginA, FruchtS, GudesblattM, DhawanV, LesserM, VonsattelJP, FahnS, EidelbergD (2010) Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol9, 149–158.
7.
HallS, OhrfeltA, ConstantinescuR, AndreassonU, SurovaY, BostromF, NilssonC, HakanW, DecraemerH, NaggaK, MinthonL, LondosE, VanmechelenE, HolmbergB, ZetterbergH, BlennowK, HanssonO (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol69, 1445–1452.
8.
MagdalinouNK, PatersonRW, SchottJM, FoxNC, MummeryC, BlennowK, BhatiaK, MorrisHR, GiuntiP, WarnerTT, de SilvaR, LeesAJ, ZetterbergH (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry86, 1240–1247.
9.
HanssonO, JanelidzeS, HallS, MagdalinouN, LeesAJ, AndreassonU, NorgrenN, LinderJ, ForsgrenL, ConstantinescuR, ZetterbergH, BlennowK (2017) Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology88, 930–937.
10.
PotashkinJA, SantiagoJA, RavinaBM, WattsA, LeontovichAA (2012) Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients. PLoS One7, e43595.
11.
SantiagoJA, PotashkinJA (2014) A network approach to diagnostic biomarkers in progressive supranuclear palsy. Mov Disord29, 550–555.
12.
SantiagoJA, PotashkinJA (2014) A network approach to clinical intervention in neurodegenerative diseases. Trends Mol Med20, 694–703.
13.
SantiagoJA, BotteroV, PotashkinJA (2018) Evaluation of RNA blood biomarkers in the Parkinson’s Disease Biomarkers Program. Front Aging Neurosci10, 157.
SantiagoJA, PotashkinJA (2017) Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson’s Disease. J Parkinsons Dis7, 653–660.
17.
SantiagoJA, LittlefieldAM, PotashkinJA (2016) Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease. Sci Rep6, 34579.
18.
SantiagoJA, PotashkinJA (2015) Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease. Proc Natl Acad Sci U S A112, 2257–2262.
19.
SantiagoJA, PotashkinJA (2015) Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s disease patients. PLoS One10, e0142582.
20.
WuY, ZhangY, HanX, LiX, XueL, XieA (2016) Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurol Sci37, 1923–1929.
21.
HerranE, RequejoC, Ruiz-OrtegaJA, AristietaA, IgartuaM, BengoetxeaH, UgedoL, PedrazJL, LafuenteJV, HernandezRM (2014) Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease. Int J Nanomedicine9, 2677–2687.
22.
TianY, SunS, TangC, WangJ, ChenX, QiaoX (2006) Intrastriatal gene transfer of vascular endothelial growth factor rescues dopaminergic neurons in a rat Parkinson’s disease model. J Huazhong Univ Sci Technolog Med Sci26, 670–673.
23.
KarinM, GallagherE (2005) From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life57, 283–295.
24.
KeyseSM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev27, 253–261.
25.
TanJ, TownT, MoriT, WuY, SaxeM, CrawfordF, MullanM (2000) CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci20, 7587–7594.
